Peter Wehrwein, Managing Editor

Ronanki says the differentiators for Lyric are a subscription-based model; being a platform that allows for technology integration and scale; and transparency.

Ben Scharfe, CPA, shares how his career-changing advice came from an unlikely person.

Executive vice president of artificial intelligence, Altera Digital Health. Altera Digital Health provides digital services to healthcare clients.

Manager of formulary operations and strategy, Yale Health. Yale Health is a not-for-profit, physician-led health maintenance organization that provides integrated, patient-centered care to the university community.

Vice president and market executive at Highmark Health. Highmark Health is a national health and wellness organization serving nearly 50 million Americans.

CEO at Serve You Rx. Serve You Rx is a midmarket pharmacy benefit manager (PBM) for self-funded employers.

Senior director of clinical programs at Capital Rx Capital Rx is an enterprise health technology company and public benefit Capital Rx is an enterprise health technology company and public benefit corporationbthat provides various healthcare benefit administration solutions for commercial, Medicare and Medicaid plans.

Vice president of postacute care solutions at OneHome. OneHome is a postacute services business for Medicare Advantage members offering engaged, at-risk network oversight for home healthcare, skilled nursing facilities, durable medical equipment and infusion services.

Director of clinical effectiveness and operations at Prime Therapeutics LLC. Prime Therapeutics is a pharmacy benefits manager owned by 19 Blue Cross and Blue Shield plans.

Chief of pharmacy at CareAllies. CareAllies is a population health company that supports physician practices and health plans.

Co-founder and chief clinical officer, InStride Health. InStride Health provides evidence-based care for children, teens and young adults with anxiety and obsessive-compulsive disorder (OCD) and their families.

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article published in the American Journal of Hematology.

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV infections.

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, SAT-3247.

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific officer says the complexity of Duchenne muscular dystrophy may ultimately mean that a number of different therapies will be used together,

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking behind it.

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

In a recent conversation with Managed Healthcare Executive, Hunter shared reflections on his tenure, the challenges of expanding impact through partnerships and what he believes sets CareOregon apart from typical insurance organizations.

Results published in Blood suggest that Jakafi (ruxolitinib) might be used on a preventive basis. A trial comparing Jakafi to posttransplant cyclophosphamide is underway.

In a conversation with Managed Healthcare Executive, Hunter expressed that work requirements are an effective way to manage Medicaid eligibility, but what is proposed will cause more harm to those who can't afford commercial healthcare.

In this second part of a video series, Managed Healthcare Executive caught up with CareOregon CEO Eric C. Hunter, who voiced concern about the consequences of rising anti-DEI views and potential federal funding cuts.

Eric C. Hunter, president and CEO of CareOregon, spoke with Managed Healthcare Executive about the state’s innovative programs and the risks posed by uncertain federal funding.

In this final interview of a three-part video series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, told MHE, in response to our recent annual Pharmacy Survey results, that FDA drug approval delays due to government cuts are happening but not widespread yet. He added that early signs and staffing challenges suggest the situation could worsen over time.

Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his insights on the results of Managed Healthcare Executive’s annual Pharmacy Survey in this part-two interview of a three-video series. In the interview, he discussed survey respondents’ views on Alzheimer’s disease as a leading driver of rising U.S. drug spending over the next three years. More than 100 healthcare industry experts took part in this year’s survey.

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers can afford to cover them and about wasteful prescriptions.